title: Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80 mL: a prospective randomized study.
abstract: OBJECTIVE
  To compare the efficacy and safety of transurethral enucleation and resection of the prostate (TUERP) and transvesical prostatectomy (TVP) for patients with benign prostatic hyperplasia (BPH) and prostate volumes >80 mL.
  
  
  METHODS
  A total of 100 patients with urodynamic obstruction and prostate volume >80 mL were prospectively randomized and enrolled in the study at a tertiary hospital. Patients underwent TVP or TUERP performed by one of two surgeons with experience of a large number of cases. All patients were preoperatively evaluated using patient age, prostate volume measurement, clinical characteristics of digital rectal examination, self-assessment using the International Prostate Symptom Scores (IPSS) questionnaire, a quality-of-life (QoL) questionnaire, maximum urinary flow rate (Qmax ), post-void residual urine volume (PVR), urine analysis, blood sample analysis, including determination of prostate-specific antigen (PSA) and haemoglobin concentration. All patients were assessed peri-operatively and postoperatively at 3 and 12 months. All complications were documented.
  
  
  RESULTS
  Of 100 patients eligible to participate, 92 patients completed 12 months of follow-up. Patients who underwent TUERP had shorter catheterization times and hospital stays. Operation duration was not significantly different between the two surgical groups (P = 0.107). The resected adenoma weight in the TVP group was more than that in the TUERP group, but the difference was not significant (P = 0.062). There were no significant differences in IPSS, PVR, Qmax or QoL scores between the groups at 3 and 12 months. The patients in the TVP group appeared to have a better Qmax at 3 months, however, the difference was not significant (P = 0.081). Adverse events were similar in the two groups.
  
  
  CONCLUSIONS
  We found that TUERP had efficacy and safety equivalent to that of TVP for patients with BPH and prostate volume >80 mL.
authors.affiliation: Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
authors.forename: Rubiao
authors.initials: R
authors.lastname: Ou
authors.forename: Xiangrong
authors.initials: X
authors.lastname: Deng
authors.forename: Wenjun
authors.initials: W
authors.lastname: Yang
authors.forename: Xinghua
authors.initials: X
authors.lastname: Wei
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
authors.forename: Keji
authors.initials: K
authors.lastname: Xie
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D009929:Organ Size; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology* / Q000601:surgery*; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000473:pathology* / Q000601:surgery*; D020728:Transurethral Resection of Prostate; D001743:Urinary Bladder